This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With the launch of Regeneron/Sanofi’s first-in-class PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, Praluent, in July 2015 and the following launch of Amgen’s PCSK9 inhibitor, Repatha, shortly after, the treatment of dyslipidaemia has once again been thrust into the limelight, with efficacy and cost of novel treatment at the forefront of discussion